AIICHI SANKYO Sets up Affiliate in Turkey * Japanese Pharmaceutical Company Establishes its own Turkish Subsidiary * Important Step in Global Expansion

Istanbul (Turkey) 13 May (PROTEXT/PRNewswire) - DAIICHI SANKYO, one of theworld's leading research-driven pharmaceutical companies based in Japan, isestablishing its own subsidiary in Turkey. The company, to be calledDAIICHI SANKYO Ilaç Tikaret Ltd., will be headquartered in Istanbul andwill initially focus on marketing the osteoporosis medication Evista(Raloxifen).

"Entering the Turkish market represents a major step in the expansion ofour global presence," said Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE.

"With this decision, we are moving closer to achieving our goal of becomingone of Europe's leading pharmaceutical companies by 2015." Over the middleterm, the company intends to significantly expand its line of medications,particularly with drugs coming from the company research pipeline to treatcardiovascular diseases. In addition, the company is interested inacquiring products and signing licensing agreements.

IMS Health, a leading international market-research institute in thepharmaceutical sector, expects Turkey to become one of the world's top tenpharmaceutical markets by 2010: "A multinational pharmaceutical group likeDAIICHI SANKYO has to be located there," Bauer said.

The affiliate in Turkey will be strategically managed from Germany, wherethe European headquarters of the Japanese pharmaceutical company is located.

The Munich office directs the company's affiliates in 10 other Europeancountries where the company has had subsidiaries for a long period of time.

These countries include major western European pharmaceutical markets likeGermany, France, Great Britain, Spain and Italy.

About DAIICHI SANKYO

DAIICHI SANKYO is a global pharmaceutical company that focuses exclusivelyon researching and marketing innovative medications. The company wascreated in 2005 through the merger of two traditional Japanese enterprises,Daiichi and Sankyo. With net sales of almost 5.5 billion eur in fiscal year2007, DAIICHI SANKYO is one of the world's leading pharmaceuticalcompanies. The company's world headquarters is in Tokyo, and its Europeanbase is located in Munich. DAIICHI SANKYO has affiliates in 11 Europeancountries and has been one of the strongest Japanese pharmaceuticalcompanies located in Europe since it set up European production facilitiesand marketing offices in 1990. The company's research activities focus onthe areas of cardiovascular diseases, hematology, diabetes, anti-infectivesand cancer. Its aim is to develop medications that are "best" in theirclass or to create new classes of pharmaceutical drugs.

Forward-looking statements

This press release contains forward-looking statements and informationabout future developments in the sector, and the legal and businessconditions of DAIICHI SANKYO EUROPE GmbH. Such forward-looking statementsare uncertain and are subject at all times to the risks of change,particularly to the usual risks faced by a global pharmaceutical company,including the impact of the prices for products and raw materials,medication safety, changes in exchange rates, government regulations,employee relations, taxes, political instability and terrorism as well asthe results of independent demands and governmental inquiries that affectthe affairs of the company.

All forward-looking statements contained in this release hold true as ofthe date of publication. They do not represent any guarantee of futureperformance. Actual events and developments could differ materially fromthe forward-looking statements that are explicitly expressed or implied inthese statements. DAIICHI SANKYO EUROPE GmbH assumes no responsibility forthe updating of such forward-looking statements about future developmentsof the sector, legal and business conditions and the company.

Dr. Thomas Portz

Corporate Communications

Phone: +49-(0)-78-08-468

E-mail: thomas.portz@daiichi-sankyo.eu

Olaf Lamberz

Corporate Communications

Phone: +49-(0)-78-08-442

E-mail: olaf.lamberz@daiichi-sankyo.eu

Source: DAIICHI SANKYO EUROPE GmbH

Contact: Dr. Thomas Portz, Corporate Communications, phone:+49-(0)-78-08-468, e-mail: thomas.portz@daiichi-sankyo.eu, Olaf Lamberz,Corporate Communications, phone: +49-(0)-78-08-442, e-mail:olaf.lamberz@daiichi-sankyo.eu

Subscribers please note that material bearing the label "PROTEXT" is notpart of CTK's news service and is not to be published under the "CTK"label. Protext is a commercial service providing distribution of pressreleases from clients, who are identified in the text of Protext reportsand who bear full responsibility for their contents.

PROTEXT